Non-Tuberculous Mycobacterial (NTM) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Non-Tuberculous Mycobacterial (NTM) Emerging Therapy and TPP Insights

Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Non-Tuberculous Mycobacterial (NTM) Overview

Non-tuberculous mycobacterial (NTM) pulmonary disease is a chronic, progressive, and highly morbid respiratory infection caused by ubiquitous environmental mycobacteria, most predominantly the Mycobacterium avium complex (MAC) and the highly resistant Mycobacterium abscessus. The disease opportunistically exploits compromised structural lung architecture—most notably in patients with underlying bronchiectasis, cystic fibrosis, or chronic obstructive pulmonary disease (COPD)—driving relentless granulomatous inflammation and irreversible pulmonary destruction. Diagnosis requires a rigorous triad of symptomatic presentation, definitive high-resolution computed tomography (HRCT) evidence of nodular or cavitary opacities, and strict microbiological confirmation. Because these pathogens form impenetrable biofilms and exhibit profound intrinsic antibiotic resistance, the standard of care mandates heavily burdensome, multidrug antimicrobial regimens (typically anchored by a macrolide) sustained for a minimum of 12 months post-culture conversion. Due to severe systemic toxicities, poor tolerability, and high clinical failure rates associated with conventional systemic therapies, the modern management paradigm for refractory disease increasingly leverages targeted, inhaled liposomal formulations of aminoglycosides; this approach delivers high-concentration bactericidal activity directly to the pulmonary macrophages while critically mitigating systemic adverse effects.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Non-Tuberculous Mycobacterial (NTM) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026